Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2499${count})

  • LRRK2 Biology Consortium, 2017
    From Structure to Function: Targeting LRRK2-mediated Parkinson's Disease

    Study Rationale:
    Parkinson's disease (PD) mutations in the LRRK2 protein have been linked to decreased GTPase (enzyme that binds to G proteins) activity and increased kinase (enzyme that modifies a...

  • LRRK2 Biology Consortium, 2017
    Consequences of LRRK2 Rab Phosphorylation in Neurons and Astrocytes

    Study Rationale:
    Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are important contributors to LRRK2-linked Parkinson's disease (PD); therefore, LRRK2 is an important drug target. The goal...

  • Improved Biomarkers and Clinical Outcome Measures, 2016
    Supramolecular Hosts as Combined Protein Aggregation Inhibitors and Hyperpolarized MRI Reporters

    Study Rationale:
    Amyloid fibrils play a key role in Parkinson's disease (PD) and monitoring of their formation from self‐assembled insoluble molecular aggregates would be extremely valuable as a...

  • Research Grant, 2016
    Parkinson's Disease Genetics Sequencing Consortium

    Study Rationale:
    The Parkinson's Disease Genetics Sequencing Consortium (PDGSC) was established following a National Institute of Neurological Disorders and Stroke workshop in June 2014 and brings...

  • Research Grant, 2017
    Validation of the Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) for Parkinson's Disease

    Study Rationale:
    The US Food and Drug (FDA) requires acceptable outcome measures to approve a cognitive-enhancing medication for the treatment of mild cognitive impairment (MCI) in Parkinson's disease...

  • Research Grant, 2017
    A Proof-of-Concept Study of Mitochondrial Drugs in Pre-Clinical Models of Parkinson’s Disease

    Study Rationale:
    Mitochondrial dysfunction (powerhouse of the cell), free-radical induced injury (highly reactive atoms that can be harmful) and inflammatory mechanisms have been proposed to play a...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.